美沙拉嗪联合双歧三联活菌在溃疡性结肠炎治疗中的应用价值分析

Analysis of application value of mesalazine combined with bifidobacterium triple viable bacteria in the treatment of ulcerative colitis

目的探析溃疡性结肠炎(UC)治疗过程中采取美沙拉嗪联合双歧三联活菌治疗的价值。方法66例溃疡性结肠炎患者,采用随机数字表法分为观察组与对照组,每组33例。对照组患者采取美沙拉嗪治疗,观察组患者采用美沙拉嗪联合双歧三联活菌治疗。比较两组患者的肠黏膜功能指标(内毒素、D-乳酸、二胺氧化酶)水平,症状(脓血便、腹泻、腹痛)消失时间,不良反应发生情况,炎症因子[白细胞介素-6(IL-6)、白细胞介素-10(IL-10)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)]水平。结果治疗后,观察组患者的内毒素(7.38±0.01)ng/L、D-乳酸(3.28±0.94)ng/L、二胺氧化酶(5.07±0.26)mg/L低于对照组的(10.20±0.93)ng/L、(5.08±0.30)ng/L、(6.38±0.36)mg/L,差异具有统计学意义(P<0.05)。观察组患者的腹痛、腹泻、脓血便消失时间分别为(2.20±0.51)d、(11.81±2.51)h、(3.11±1.41)d,均短于对照组的(3.63±0.73)d、(14.83±3.51)h、(4.81±2.51)d,差异具有统计学意义(P<0.05)。观察组患者的不良反应发生率3.03%低于对照组的21.21%,差异具有统计学意义(P<0.05)。治疗后,观察组患者的IL-10(69.34±8.55)ng/L高于对照组的(47.31±7.65)ng/L,IL-8(155.22±25.32)ng/L、IL-6(90.22±15.68)ng/L、TNF-α(18.14±6.51)ng/L低于对照组的(205.31±30.22)、(140.22±20.54)、(29.52±8.54)ng/L,差异具有统计学意义(P<0.05)。结论美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎可以有效减轻炎症因子水平,缓解患者临床症状,且改善肠黏膜功能,加快康复进度,同时不良反应较少。

Objective To discuss and analyze the value of mesalazine combined with bifidobacterium triple viable bacteria in the treatment of ulcerative colitis(UC).Methods A total of 66 patients with ulcerative colitis were divided into observation group and control group by random numerical table,with 33 cases in each group.Patients in the control group were treated with mesalazine,and patients in the observation group were treated with mesalazine combined with bifidobacterium triple viable bacteria.Both groups were compared in terms of intestinal mucosal function indicators(endotoxin,D-lactic acid,diamine oxidase),disappearance time of symptoms(purulent and bloody stool,diarrhea,abdominal pain),occurrence of adverse reactions,inflammatory factors[interleukin-6(IL-6),interleukin-10(IL-10),interleukin-8(IL-8),tumor necrosis factorα-(TNF-α)]levels.Results After treatment,the levels of endotoxin(7.38±0.01)ng/L,D-lactic acid(3.28±0.94)ng/L,and diamine oxidase(5.07±0.26)mg/L in the observation group were lower than(10.20±0.93)ng/L,(5.08±0.30)ng/L,and(6.38±0.36)mg/L in the control group,and the differences were all statistically significant(P<0.05).The disappearance time of abdominal pain,diarrhea,purulent and bloody stool in the observation group were(2.20±0.51)d,(11.81±2.51)h and(3.11±1.41)d,which were shorter than(3.63±0.73)d,(14.83±3.51)h and(4.81±2.51)d in the control group,and the differences were all statistically significant(P<0.05).The incidence of adverse reactions 3.03%in the observation group was lower than 21.21%in the control group,and the difference was statistically significant(P<0.05).After treatment,the IL-10(69.34±8.55)ng/L in the observation group was higher than(47.31±7.65)ng/L in the control group;the IL-8(155.22±25.32)ng/L,IL-6(90.22±15.68)ng/L,TNF-α(18.14±6.51)ng/L in the observation group were lower than(205.31±30.22),(140.22±20.54),(29.52±8.54)ng/L in the control group;the differences were all statistically significant(P<0.05).Conclusion Mesalazine combined with bifidobacterium triple viable bacteria in the treatment of ulcerative colitis can effectively reduce the level of inflammatory factors,alleviate the clinical symptoms of patients,improve the function of intestinal mucosa,accelerate the progress of rehabilitation with fewer adverse reactions.